Lumida
/TVRD
⌘K
Tvardi Therapeutics Inc

Tvardi Therapeutics Inc

TVRD
$1.87USD↑+1.91%+0.04 today

MARKET CAP

24.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$2
$44

AI Summary

Stalk
StalkMedium

TVRD is carving an early-stage Stage 1 consolidation after a steep decline, with flat 9/21 EMAs hugging price and subdued volume. The asset sits at extreme oversold levels within a horizontal base range, offering a medium-term bullish mean-reversion opportunity. Short-term timing is neutral due to lack of decisive acceptance or breakout. The recommended posture is to stalk long entries near the EMA cluster and lower boundary, awaiting clear price acceptance above these structural support levels.

  • ↑Healthy volunteer data show TTI-101 reduced disease-relevant immune cells.
  • ↑$15.8 M cash reserves fund operations into Q3 2027.
  • ↓Q2 2026 net loss $6.5 M; EPS -$0.69 missed -$0.63 consensus.
Full analysis →

Buying

0

institutions

Selling

5

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL95.48 K181.41 K+-292.60 K-85.3%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL91.41 K173.68 K+-691.00-40.7%0.00%
FC

Farallon Capital Management LLC

Q1 2026

SELL21.44 K68.17 K+-21.79 K-63.3%0.00%
AC

Aqr Capital Management LLC

Q2 2026

SELL27.10 K51.48 K+-15.10 K-61.6%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL126.00240.00+-2.44 K-97.1%0.00%